Abstract:Infection by the intracellular bacterial pathogen Mycobacterium tuberculosis (Mtb) is a major cause of morbidity and mortality worldwide. Slow progress has been made in lessening the impact of tuberculosis (TB) on human health, especially in parts of the world where Mtb is endemic. Due to the complexity of TB disease, there is still an urgent need to improve diagnosis, prevention, and treatment strategies to control global spread of disease. Active research targeting avenues to prevent infection or transmission through vaccination, to diagnose asymptomatic carriers of Mtb, and to improve antimicrobial drug treatment responses is ongoing. However, this research is hampered by a relatively poor understanding of the pathogenesis of early infection and the factors that contribute to host susceptibility, protection, and the development of active disease. There is increasing interest in the development of adjunctive therapy that will aid the host in responding to Mtb infection appropriately thereby improving the effectiveness of current and future drug treatments. In this review, we summarize what is known about the host response to Mtb infection in humans and animal models and highlight potential therapeutic targets involved in TB granuloma formation and resolution. Strategies designed to shift the balance of TB granuloma formation toward protective rather than destructive processes are discussed based on our current knowledge. These therapeutic strategies are based on the assumption that granuloma formation, although thought to prevent the spread of the tubercle bacillus within and between individuals contributes to manifestations of active TB disease in human patients when left unchecked. This effect of granuloma formation favors the spread of infection and impairs antimicrobial drug treatment. By gaining a better understanding of the mechanisms by which Mtb infection contributes to irreversible tissue damage, down regulates protective immune responses, and delays tissue healing, new treatment strategies can be rationally designed. Granuloma-targeted therapy is advantageous because it allows for the repurpose of existing drugs used to treat other communicable and non-communicable diseases as adjunctive therapies combined with existing and future anti-TB drugs. Thus, the development of adjunctive, granuloma-targeted therapy, like other host-directed therapies, may benefit from the availability of approved drugs to aid in treatment and prevention of TB. In this review, we have attempted to summarize the results of published studies in the context of new innovative approaches to host-directed therapy that need to be more thoroughly explored in pre-clinical animal studies and in human clinical trials.

Host and bacterial lipid metabolism during tuberculosis infections: possibilities to synergise host- and bacteria-directed therapies

Revolutionizing control strategies against Mycobacterium tuberculosis infection through selected targeting of lipid metabolism

Metabolic Versatility of Mycobacterium tuberculosis during Infection and Dormancy

The uncharted territory of host-pathogen interaction in tuberculosis

The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development

Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review

Mycobacterium tuberculosis and lipids: Insights into molecular mechanisms from persistence to virulence

Sphingolipids: A double-edged sword in the defense against Mycobacterium tuberculosis.

Roles of Lipolytic enzymes in Mycobacterium tuberculosis pathogenesis

Host cell environments and antibiotic efficacy in tuberculosis

Decoding the role of mycobacterial lipid remodelling and membrane dynamics in antibiotic tolerance

Lactate Metabolism and Signaling in Tuberculosis and Cancer: A Comparative Review

[Biosynthesis and regulation of mycolic acids in Mycobacterium tuberculosis--a review].

Targeting host-specific metabolic pathways—opportunities and challenges for anti-infective therapy

Mycobacterium tuberculosis inhibition of phagolysosome biogenesis and autophagy as a host defence mechanism

The impact of Mycobacterium tuberculosis on the macrophage cholesterol metabolism pathway

Repurposing diphenylbutylpiperidine-class antipsychotic drugs for host-directed therapy of Mycobacterium tuberculosis and Salmonella enterica infections

Identification of Host-Targeted Small Molecules That Restrict Intracellular Mycobacterium tuberculosis Growth

Mycobacterium tuberculosis overcomes phosphate starvation by extensively remodelling its lipidome with phosphorus-free lipids

Antituberculosis Therapy and Gut Microbiota: Review of Potential Host Microbiota Directed-Therapies

Recent Advances in Antitubercular Compounds Targeting Mycolic Acid Biosynthesis and Transport